AstraZeneca (LON:AZN) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

AstraZeneca PLC (LON:AZN)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of £126.75 and traded as high as £138.38. AstraZeneca shares last traded at £137.80, with a volume of 34,225,715 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on AZN shares. Berenberg Bank increased their price target on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Citigroup initiated coverage on AstraZeneca in a report on Tuesday, January 27th. They issued a “buy” rating and a £170 price target for the company. Deutsche Bank Aktiengesellschaft lifted their price target on AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research note on Thursday, January 15th. Jefferies Financial Group reiterated a “buy” rating and issued a £150 price objective on shares of AstraZeneca in a research report on Monday, November 10th. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday, January 16th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of £145.83.

AstraZeneca Stock Down 0.3%

The firm has a 50 day moving average of £137.47 and a two-hundred day moving average of £126.75. The stock has a market capitalization of £213.63 billion, a PE ratio of 22.89, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83.

Insider Activity

In related news, insider Nazneen Rahman sold 297 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of £134.96, for a total value of £40,083.12. 0.15% of the stock is owned by company insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.